\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Associated Publications}{}% 5
\BOOKMARK [0][-]{chapter*.7}{Contents}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Figures}{}% 7
\BOOKMARK [0][-]{chapter*.10}{List of Tables}{}% 8
\BOOKMARK [0][-]{chapter*.11}{Abbreviations}{}% 9
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 10
\BOOKMARK [1][-]{section.1.1}{Psoriasis and psoriatic arthritis}{chapter.1}% 11
\BOOKMARK [2][-]{subsection.1.1.1}{Epidemiology and global impact}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.2}{Psoriasis and inflammatory dermatoses}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.3}{PsA and spondyloarthropaties}{section.1.1}% 14
\BOOKMARK [1][-]{section.1.2}{Pathophysiology of psoriasis and psoriatic arthritis}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.2.1}{Clinical presentation and diagnosis}{section.1.2}% 16
\BOOKMARK [2][-]{subsection.1.2.2}{Aetiology of psoriasis and PsA}{section.1.2}% 17
\BOOKMARK [2][-]{subsection.1.2.3}{Cell types involved in psoriasis and PsA pathogenesis}{section.1.2}% 18
\BOOKMARK [2][-]{subsection.1.2.4}{Therapeutic intervention}{section.1.2}% 19
\BOOKMARK [1][-]{section.1.3}{Genetics of psoriasis and psoriatic arthritis}{chapter.1}% 20
\BOOKMARK [2][-]{subsection.1.3.1}{Heritability}{section.1.3}% 21
\BOOKMARK [2][-]{subsection.1.3.2}{Non-GWAS and linkage studies}{section.1.3}% 22
\BOOKMARK [2][-]{subsection.1.3.3}{Genome-wide association studies}{section.1.3}% 23
\BOOKMARK [2][-]{subsection.1.3.4}{Relevance of non-coding versus coding variants in disease susceptibility}{section.1.3}% 24
\BOOKMARK [2][-]{subsection.1.3.5}{The role of GWAS studies in highlighting immune-relevant cell types and pathways}{section.1.3}% 25
\BOOKMARK [2][-]{subsection.1.3.6}{Limitations and future of GWAS studies}{section.1.3}% 26
\BOOKMARK [1][-]{section.1.4}{Functional interpretation of genome-wide association studies in complex diseases}{chapter.1}% 27
\BOOKMARK [2][-]{subsection.1.4.1}{Overcoming the limitations of GWAS: post-GWAS studies}{section.1.4}% 28
\BOOKMARK [2][-]{subsection.1.4.2}{The use of fine-mapping to prioritise causal variants}{section.1.4}% 29
\BOOKMARK [2][-]{subsection.1.4.3}{Understanding the epigenetic landscape in complex diseases}{section.1.4}% 30
\BOOKMARK [2][-]{subsection.1.4.4}{The chromatin landscape}{section.1.4}% 31
\BOOKMARK [2][-]{subsection.1.4.5}{Transcriptional profiles in disease}{section.1.4}% 32
\BOOKMARK [2][-]{subsection.1.4.6}{Transcriptional regulation in complex diseases}{section.1.4}% 33
\BOOKMARK [2][-]{subsection.1.4.7}{Integration and interpretation of genomic data}{section.1.4}% 34
\BOOKMARK [2][-]{subsection.1.4.8}{Immunophenotyping}{section.1.4}% 35
\BOOKMARK [2][-]{subsection.1.4.9}{Approaches to establish disease mechanisms and causality of genetic variant}{section.1.4}% 36
\BOOKMARK [0][-]{chapter.2}{Establishment of laboratory methods and analytical tools to assess genome-wide chromatin accessibility in clinical samples}{}% 37
\BOOKMARK [1][-]{section.2.1}{Introduction}{chapter.2}% 38
\BOOKMARK [1][-]{section.2.2}{Results}{chapter.2}% 39
\BOOKMARK [2][-]{subsection.2.2.1}{Establishment of an ATAC-seq data analysis pipeline based on current knowledge}{section.2.2}% 40
\BOOKMARK [2][-]{subsection.2.2.2}{Assessment of ATAC-seq transposition times and comparison with FAST-ATAC protocol in relevant cell types}{section.2.2}% 41
\BOOKMARK [2][-]{subsection.2.2.3}{Limitations of ATAC-seq and FAST-ATAC to assess chromatin accessibility in KC}{section.2.2}% 42
\BOOKMARK [2][-]{subsection.2.2.4}{Discussion}{section.2.2}% 43
\BOOKMARK [0][-]{chapter.3}{Cross-tissue comparison of chromatin accessibility, gene expression signature and immunophenotypes in PsA}{}% 44
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 45
\BOOKMARK [1][-]{section.3.2}{Results}{chapter.3}% 46
\BOOKMARK [2][-]{subsection.3.2.1}{PsA patients cohort description and datasets}{section.3.2}% 47
\BOOKMARK [2][-]{subsection.3.2.2}{Differences in the chromatin accessibility landscape between circulating and SF immune cells}{section.3.2}% 48
\BOOKMARK [2][-]{subsection.3.2.3}{Differential gene expression analysis in paired circulating and synovial immune cells}{section.3.2}% 49
\BOOKMARK [1][-]{section.3.3}{Discussion}{chapter.3}% 50
